Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$16.72M+545.81%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Garrett Smallwood
- Sector
- Technology
- Industry
- Software - Application
- Employees
- 64
- Beta
- 1.26
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -11.67
Financials
Revenue
$16.72M+545.8%Net Income
$-6.14MEBITDA
$-3.76MFree Cash Flow
$-2.87MEPS (diluted)
$-0.12Shares Outstanding (diluted)
50.80M+33.9%Operating Expenses
$17.02MCash & Debt
$2.67MRevenue by Segment (annual)
$64.30MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2024 | $70.51M | $-17.57M | $-0.39 |
| 2023 | $83.92M | $-13.32M | $-0.35 |
| 2022 | $54.87M | $-38.57M | $-2.07 |
| 2021 | $20.08M | $-6.31M | $-0.17 |
| 2020 | $11.97M | $-18.84M | $-0.50 |
Valuation
PEThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
107+6.67%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·30d ago·Neutral
Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More Voyager Therapeutics, Inc. remains a Strong Buy, driven by dual anti-tau programs targeting Alzheimer's Disease with key catalysts in late 2026 and 2027. Company expects phase 1b PET imaging efficacy data for VY7523 in Q4 2026 and first-in-human dosing of gene therapy VY1706 for AD in the same quarter. Strategic partnerships with Novartis, Neurocrine, and AstraZeneca have secured $500M+ in non-dilutive funding and potential $6…
View source ↗ - Newsglobenewswire.com·44d ago·Neutral
…ucation Agreement to Advance PSMA-Informed Prostate Care Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans TORONTO, Oct. 09, 2026 (GLOBE NEWSWIR…
View source ↗ - Newszacks.com·46d ago·Neutral
BASF Expands Ultradur Portfolio With Recycled PET Grades BASFY expands Ultradur RC1 with up to 30% recycled PET, targeting high-performance automotive parts and customers' sustainability goals.
View source ↗ - Newszacks.com·47d ago·Neutral
GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal GEHC's $945M SOFIE Biosciences deal will expand its U.S. PET radiopharmaceutical footprint and boost exposure to precision care growth.
View source ↗ - Newswsj.com·48d ago·Neutral
GE HealthCare is expected to announce Monday a $945 million cash purchase of a manufacturer of radioactive substances used in medical imaging procedures like PET scans The deal expands GE HealthCare's footprint in radiopharmaceuticals, its fastest-growing segment.
View source ↗ - Newsproactiveinvestors.com·95d ago·Neutral
Grey Matters Health taps ProScan for brain PET scan interpretation in Florida Grey Matters Health (CSE:GREY, OTCQB:AGNPD, FRA:AGW0) announced that it has signed a professional services agreement with ProScan Reading Services to interpret brain PET scans from its planned NovaScan Neuroimaging Clinics location in Davie, Florida. The clinic, which Grey Matters expects to open by September 30, will use ProScan's fellowship-trained, board-certified subspecialty radiologists to interpret scans for pat…
View source ↗
Earnings
Typical surprise -71.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, May 12$-0.10 vs $-0.07miss
- Mon, Mar 24$-0.10 vs $-0.05miss
- Wed, Nov 13$-0.13 vs $-0.04miss
- Wed, Aug 7$-0.06 vs $-0.06beat
Estimates and results for PET via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PET officers and directors.
- Bought
- $1.7m
- Sold
- $1.9m
6 trades
72 trades
- Szabo John P Jrsold
- Szabo John P Jrsold
- Szabo John P Jrsold
- Davidian Alecsold
- Davidian Alecsold
- Cane Davidsold
- Cane Davidsold
- Mccarthy Patricksold
22 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PET.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
